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itive procedure for many cardiac anomalies in which the
size or function of only one ventricle is adequate. One
of the recognized complications after the Fontan proce-
dure is thromboembolism both early and late after the
operation. Along with arterial embolization to the cen-
tral nervous system resulting in persistent neurologic
deficit, pulmonary thromboembolism has also been
reported.2,3 According to Virchow’s triad (characterized
by loss of endothelial cell function, slow or turbulent
blood flow, and hypercoagulability state), the risk of
thromboembolism could be increased in this setting by
hemodynamic factors, the presence of artificial materi-
al, or coagulation abnormalities. A number of authors
have analyzed a variety of possible predisposing fac-
tors, including demographic and surgical factors
The Fontan operation was initially reported for thesurgical management of tricuspid atresia in 1971.1
Since 1971, various modifications have been introduced
and now cavopulmonary anastomosis is used as a defin-
Objective: Low-velocity and nonlaminar flow patterns in the Fontan circula-
tion, as well as abnormal liver function in some patients, may partly account
for the coagulation abnormalities seen. We examined (1) coagulation factor
abnormalities before and after the Fontan procedure and (2) regional coagu-
lation factor abnormalities in the Fontan circulation. 
Methods: Levels of factors V, VII, VIII, X, antithrombin III, prothrombin
fragment F1+2, protein C, and protein S were measured in 2 groups of
patients: In 14 patients undergoing the Fontan procedure, blood was ana-
lyzed before the operation and 5 days after the operation (group 1). The
median age in this group was 3.2 years. In 10 patients who had undergone
the Fontan procedure, cardiac catheterization was performed and samples
were taken from the femoral vein, inferior vena cava, right atrium, and pul-
monary artery (group 2). The median age in this group was 6.2 years and the
median follow-up from the Fontan procedure was 4.1 years. 
Results: In group 1 a significant increase was noted postoperatively in the
concentration of factor VIII (P < .001), factor X (P < .001), and prothrom-
bin fraction F1+2 (P < .001). A significant decrease in the levels of
antithrombin III (P < .001), protein C (P < .004), and protein S (P < .02) was
also found. The increase in factors VIII and X persisted at 4 years’ follow-up
in group 2 patients. In group 2, no significant regional differences were
observed between the coagulation factors measured at different sites.
Conclusions: There is an increased tendency toward coagulation after the
Fontan procedure. A prothrombotic state is supported by thrombin genera-
tion associated with reduced antithrombin III concentration. This increase in
coagulation may contribute to the early and late risks of thromboembolism
observed after the Fontan procedure. We did not find any regional differ-
ences in coagulation abnormalities in patients late after the Fontan proce-
dure. Therefore, the mechanisms and causes of the coagulation abnormali-
ties remain unclear.  (J Thorac Cardiovasc Surg 2000;120:778-82)
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(patient age at operation; the original morphologic fea-
tures; type of Fontan procedure, including the presence
or absence of fenestration; type of material used for the
conduit; use of valved or nonvalved conduit) and hemo-
dynamic factors.4 No single predisposing factor has
emerged from these studies. This led us to believe that
coagulation abnormalities may play a role. Recent evi-
dence suggests that this may indeed be the case.5,6
In the adult population, regional left atrial coagula-
tion activity may be increased in mitral stenosis and
may contribute to the pathophysiology of left atrial
thrombus.7 Furthermore, the increase in left atrial coag-
ulation has been shown to be associated with the
echocardiographic phenomenon of left atrial sponta-
neous echo contrast.8 Similarly, abnormal flow patterns
in the Fontan circulation as demonstrated by sponta-
neous echo contrast may partly account for the coagu-
lation abnormalities seen.
Venous pressure in the liver is increased by the
Fontan procedure. Since procoagulant and anticoagu-
lant factors are produced in the liver, the increased
venous pressure of Fontan physiology might change
the usual balance of procoagulant and anticoagulant
activity. Hemodynamic factors might also have an
impact by affecting platelet aggregation with different
intensities of turbulence. Increase in platelet hyperreac-
tivity due to increased wall shear stress and flow dis-
turbance can contribute to a prothrombotic state.
We set out to assess the overall thrombotic status of
patients who have undergone the Fontan procedure and
its modifications and to assess any regional variability
in the Fontan pathway.
Patients and methods
Two groups of patients were studied.
Group 1: Fourteen patients after the Fontan procedure.
The median age in this group was 3.2 years (range, 14
months–12 years). Their morphologic diagnoses are shown in
Table I. Twelve patients underwent total cavopulmonary con-
nection and 2 patients underwent an extracardiac Fontan pro-
cedure. In this group, blood was taken before the operation
and 5 days after the operation. These time frames were cho-
sen to avoid extra venipunctures and to use the existing lines
placed during anesthesia. None of the patients was receiving
heparin or warfarin sodium (Coumadin). An activated clot-
ting time of more than 700 seconds was achieved before car-
diopulmonary bypass was begun. All patients who received
aprotinin during or after the operation were excluded from
the study. Five patients received fresh frozen plasma and 1
received platelets within 4 hours of the operation.
Group 2: Ten patients who were admitted for elective
cardiac catheterization at different points of follow-up
after their Fontan procedure. All patients had undergone
total cavopulmonary connection. The median age in this
group at the time of the study was 6.2 years (range, 3-18
years) and the median time from the Fontan repair was 4.1
years (range, 2-14 years). At the time of the elective cardiac
catheterization, blood was taken from the site of entry via the
catheter for baseline measurements, at the level of the renal
veins, in the right atrium, and in the left pulmonary artery. All
samples were taken before administration of heparin.
Blood samples were examined for coagulation factors V,
VII, VIII, and X, antithrombin III, prothrombin fragment
(F1+2), protein C, and protein S. Patients with history of
thromboembolism and clotting abnormalities, patients re-
ceiving warfarin, aspirin, or heparin, and those with protein-
losing enteropathy were excluded from the study. 
Assay procedure. Samples for factors VIII, V, VII, and X and
protein C were analyzed with an Electra 1000C coagulation
instrument (Hemoliance, Pleasantville, NY). Factors V, VII, and
X were measured with Dade deficient plasmas and thrombo-
plastin C plus reagent (Dade Behring Inc, Newark, Del). 
Protein C was assessed by a functional clotting assay based
on prolongation of the activated partial thromboplastin time
with a protein C activator. The reference range (66%-129%)
was developed in-house from normal subjects in the age
range of 2 years to adult. Protein S was measured by an
enzyme immunoassay for free protein S with the use of the
Asserechrome free protein S kit from Diagnostica Stago,
Asnieres-Sur-Seine, France. The reference range (66%-
129%) was developed in-house from normal subjects in the
age range of 2 years to adult.
Antithrombin levels were measured on a Hitachi 911
chemistry analyzer (Roche/Boehringer Mannheim, Division
of Roche Diagnostics, Mannheim, Germany) with the
Coamatic Antithrombin kit (Chromogenix, Molndal,
Sweden). This is a chromogenic method in which plasma is
incubated with an excess of factor Xa in the presence of
heparin. The residual quantity of factor Xa is determined by
age hydrolysis of the chromogenic substrate S-2765 and is
inversely proportional to the antithrombin level in the plasma.
Reference range is based on in-house study of patients being
treated for ear, nose, and throat problems (80%-130%).
The F1+2 was measured by an enzyme immunoassay tech-
nique by means of the Enzygnost F1+2 micro kit (Behring
Diagnostics GmbH, Marburg, Germany). A reference range
from 140 adults was used (0.4-1.1 nmol/L).
Statistical analysis. Data are presented in terms of the
mean and standard deviation since all variables conformed to
Table I.  Morphologic diagnosis of 14 patients who
underwent the Fontan procedure
Diagnosis No.
Unbalanced common atrioventricular canal 1
Tricuspid atresia 3
Double-outlet right ventricle, pulmonary atresia 6
Double-inlet left ventricle 3
Hypoplastic left heart (stage III) 1
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a normal distribution. Measurements of coagulation factors
and protein levels before and after the Fontan operation were
compared by paired t tests. Repeated-measures analysis of
variance with a Greenhouse-Geisser F test for small samples9
was used to determine post-Fontan differences among 4
regional sites. Analysis was performed by means of the SAS
version 6.12 software package (SAS Institute, Inc, Cary, NC).
Power analysis indicated that the 14 patients studied would
provide more than 90% power to detect an effect size of 1.0
between pre-Fontan and post-Fontan measurements. Our
sample size of 10 patients in whom post-Fontan regional site
data were obtained provided 68% power (nQuery Advisor,
version 3.0, Statistical Solutions, Boston, Mass). 
Results
Group 1 had a significant early increase, 5 days after
the Fontan procedure, in coagulation factors VIII 
(P < .001), X (P < .001), and F1+2 relative to the pre-
operative levels, whereas the levels of factor VII 
(P = .002) and antithrombin III (P < .001) decreased.
Concentrations of both protein C and protein S were
significantly lower in the postoperative period (P =
.004 and P = .02, respectively) (Table II). 
In group 2, no regional coagulation differences were
detected at the 4 sites examined late after the Fontan
procedure (Table III). The postoperative values in
group 1 were compared with the baseline measure-
ments in this group to assess whether coagulation
abnormalities persisted beyond the early postoperative
period (Table IV). The increase in factors VIII and X
persisted at 4 years’ follow-up. Factor VII remained
reduced.
Discussion
Thromboembolism is a major cause of morbidity and
mortality after the Fontan procedure and its modifica-
tions. The reported incidence of this complication has
been as high as 20% in some series.10 In this study we
have attempted to determine whether a prothrombotic
condition is present after the Fontan procedure and
whether any regional coagulation abnormalities are
present in the Fontan pathway. It is unlikely that the
results early after the Fontan procedure are affected in
the 5 patients who received fresh frozen plasma, since
its half-life is 6 hours.
We have shown a significant increase in coagulation
factors and a reduction in natural anticoagulants after
the Fontan procedure. Furthermore, we have shown a
significant increase in F1+2 concentration associated
with reduced antithrombin III level. An increase in
Table II.  Profile of coagulation factors and protein levels for group 1 patients (n = 14) measured both before and
after the Fontan operation
Before Fontan (mean ± SD) After Fontan (mean ± SD) P value
Factor V (%) 97.6 ± 26.0 86.6 ± 27.8 .22
Factor VII (%) 57.7 ± 20.4 40.8 ± 19.5 .002
Factor VIII (%) 134.1 ± 40.8 210.3 ± 55.2 <.001
Factor X (%) 58.6 ± 13.3 72.6 ± 14.2 <.001
Antithrombin III (%) 92.0 ± 14.6 74.5 ± 14.1 <.001
F1+2 (nmol/L) 0.60 ± 0.24 1.54 ± 0.63 <.001
Protein C (%) 80.1 ± 9.8 65.6 ± 11.7 .004
Protein S (%) 58.2 ± 13.9 48.1 ± 19.1 .02
F1+2, Prothrombin fragment.
Table III.  Regional measurements for group 2 (post-Fontan) patients (n = 10)
Femoral vein Renal vein Right atrium LPA
(mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD) P value
Factor V (%) 63.0 ± 18.9 61.6 ± 18.5 61.8 ± 18.9 59.2 ± 13.2 .6
Factor VII (%) 49.3 ± 16.3 47.6 ± 17.1 47.5 ± 16.4 43.5 ± 14.0 .36
Factor VIII (%) 187.4 ± 48.2 175.3 ± 43.2 171.2 ± 37.4 167.3 ± 45.7 .14
Factor X (%) 63.4 ± 12.0 62.4 ± 9.7 62.5 ± 9.5 63.2 ± 9.8 .73
Antithrombin III (%) 91.6 ± 12.7 92.3 ± 12.8 92.1 ± 12.3 89.3 ± 9.9 .56
F1+2 (nmol/L) 0.74 ± 0.50 0.34 ± 0.11 0.33 ± 0.10 0.37 ± 0.10 .09
Protein C (%) 87.8 ± 16.2 93.9 ± 20.1 92.8 ± 16.7 91.3 ± 18.9 .27
Protein S (%) 72.5 ± 15.7 73.0 ± 16.8 71.8 ± 13.7 71.0 ± 16.6 .52
LPA, Left pulmonary artery; F1+2, prothrombin fragment.
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F1+2 has previously not been reported. Thrombin gen-
eration is one of the most important contributors to a
prothrombotic state in both venous and arterial throm-
bosis. Thrombin is the most active platelet-aggregating
agent, and by forming fibrin strands it stabilizes the
fragile platelet-rich thrombus. A highly significant
increase in thrombin generation coupled with reduced
antithrombin III levels is the best and most reliable
indicator of a prothrombotic state. 
Some of these changes persisted in a second group of
patients up to 14 years after the Fontan operation. We
found no regional coagulation abnormalities in the
Fontan pathway in this latter group. 
Protein C, a vitamin K–dependent protein, is a natur-
al anticoagulant that is synthesized in the liver.11 After
activation by thrombin, protein C is a potent inhibitor
of the coagulation cascade stimulating fibrinolysis.
Protein S acts as a cofactor in this pathway, increasing
fibrinolysis.12 Therefore, deficiency of these proteins
can cause an increase in coagulation. Protein C with or
without protein S deficiency, either inherited or
acquired, has been associated with increased thrombot-
ic activity.13,14
Increase in coagulation status after the Fontan proce-
dure has previously been reported.5,6,15 Some of these
findings have been criticized for not having used an
age-appropriate range for control values.16 However,
even when age-appropriate ranges were used, these
coagulation abnormalities persisted. Cromme-Dijkhuis
and colleagues5 reported that these coagulation abnor-
malities tended to resolve as duration of follow-up
lengthened. In the present study, we have shown that
some of these coagulation abnormalities persisted at a
median follow-up of 4 years after the Fontan repair. 
An interesting observation of our study was that fac-
tor VII levels not only did not increase but decreased
after the Fontan procedure and this decrease persisted
at follow-up (group 2 patients). Experimental evidence
suggests that very low concentrations of factor VII can
support tissue factor–induced coagulation in patholog-
ic states.17 Furthermore, the risk of thromboembolism
has been shown to increase in patients with hereditary
factor VII deficiency.18
We have shown a generalized increase in coagula-
tion in the early postoperative period after the
Fontan procedure. Some of these changes have per-
sisted at 4 years’ follow-up. The practical implica-
tion of this increase may be that long-term adminis-
tration of anticoagulants after the Fontan operation
is indicated.
We thank Iren B. Kovacs, MRCPath, PhD, for reviewing
the manuscript and providing pertinent hematology advice. 
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